Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
A Growing Factor
Chicago - Palifermin, a recombinant form of human keratinocyte growth factor (rhuKGF), has been shown to significantly reduce the duration and incidence of severe oral mucositis, while lessening the use of parenteral opioid analgesics and improving the patient's outcome in patients with hematologic malignancies undergoing high-dose chemotherapy, radiotherapy, and total body irradiation (TBI) followed by hematopoietic stem-cell support, Ricardo Spielberger, M.D., said at the 39th annual meeting of the American Society of Oncology.
Related Videos
Related Content
